Compare Adaptive Biotechnologies Corp (ADPT) vs Atomera Incorporated (ATOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Atomera Incorporated — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while Atomera Incorporated trades at $6.71 (market cap $284.76M). The key difference: Adaptive Biotechnologies Corp is far larger — about 11.7× Atomera Incorporated's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Atomera Incorporated nearer its low. Which is the better fit depends on your goals.
| ADPT | ATOM | |
|---|---|---|
Market Cap | $3.33B | $284.76M |
Sector | Health | Technology |
52-Week High | $22.37 | $12.11 |
52-Week Low | $10.24 | $1.99 |
Enterprise Value | $3.19B | $244.97M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ATOM trades at $7.355, down 0.74% with bearish technical signals. The company shows severe financial distress with negative gross margins of -520.83% and net losses of -$20.17 million in 2025. Recent earnings misses and negative cash flow highlight operational challenges despite 100% analyst buy ratings. Technical indicators show bearish momentum with support at $7 and resistance at $8.
The outlook remains highly speculative given extreme financial losses and negative cash flow. Investment opportunity hinges on successful commercialization of GaN semiconductor technology, while risks include continued cash burn and failure to achieve revenue growth. The stock represents a high-risk bet on unproven technology execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →
